Floatz logo

DYNAMOS

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Yale UniversitySmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the MASH - Metabolic Dysfunction-Associated Steatohepatitis cohort.

Asset / SponsorPhaseRating
Resmetirom
City University of New York
Phase 4BBB
hsk31679
Haisco Pharmaceutical Group Co., Ltd.
Phase 3BB
Cystadane
Southern California Institute for Research and Education
Phase 2B
Chiglitazar
Shanghai Jiao Tong University School of Medicine
Phase 2CCC
Polyene Phosphatidyl Choline
Shanghai Jiao Tong University School of Medicine
Phase 2CCC
Tgm-312-Sc01
Tangram Therapeutics Plc
Phase 1/2CC
Rezdiffra
Madrigal Pharmaceuticals, Inc.
D

Same molecule, other indications

DYNAMOS is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
60 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →